Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
Klencke Barbara J, Donahue Rafe, Gorsh Boris, +3 more·Future oncology (London, England)
JAK inhibitors are the current standard of care in myelofibrosis, but many do not address and may worsen anemia; thus, anemia-related responses have traditionally been overlooked as efficacy end points in pivotal clinical trials, leading to a lack of consistency and analytic detail in their reporting. Here we apply our…